| Literature DB >> 29643800 |
Jeremiah P Hartner1, Laura A Schrader1,2.
Abstract
Spatial memory processing requires functional interaction between the hippocampus and the medial entorhinal cortex (MEC). The grid cells of the MEC are most abundant in layer II and rely on a complex network of local inhibitory interneurons to generate spatial firing properties. Stress can cause spatial memory deficits in males, but the specific underlying mechanisms affecting the known memory pathways remain unclear. Stress activates both the autonomic nervous system and the hypothalamic-pituitary-adrenal axis to release norepinephrine (NE) and glucocorticoids, respectively. Given that adrenergic receptor (AR) and glucocorticoid receptor (GR) expression is abundant in the MEC, both glucocorticoids and NE released in response to stress may have rapid effects on MEC-LII networks. We used whole-cell patch clamp electrophysiology in MEC slice preparations from male mice to test the effects of NE and glucocorticoids on inhibitory synaptic inputs of MEC-LII principal cells. Application of NE (100 μM) increased the frequency and amplitude of spontaneous inhibitory post-synaptic currents (sIPSCs) in approximately 75% of the principal cells tested. Unlike NE, bath application of dexamethasone (Dex, 1 μM), a synthetic glucocorticoid, or corticosterone (1 μM) the glucocorticoid in rodents, rapidly decreased the frequency of sIPSCs, but not miniature (mIPSCs) in MEC-LII principal cells. Interestingly, pre-treatment with Dex prior to NE application led to an NE-induced increase in sIPSC frequency in all cells tested. This effect was mediated by the α1-AR, as application of an α1-AR agonist, phenylephrine (PHE) yielded the same results, suggesting that a subset of cells in MEC-LII are unresponsive to α1-AR activation without prior activation of GR. We conclude that activation of GRs primes a subset of principal cells that were previously insensitive to NE to become responsive to α1-AR activation in a transcription-independent manner. These findings demonstrate the ability of stress hormones to markedly alter inhibitory signaling within MEC-LII circuits and suggest the intriguing possibility of modulation of network processing upstream of the hippocampus.Entities:
Keywords: grid cells; inhibitory interneurons; memory; psychological; pyramidal cells; slice preparation; stellate cells; stress
Year: 2018 PMID: 29643800 PMCID: PMC5883071 DOI: 10.3389/fnsyn.2018.00003
Source DB: PubMed Journal: Front Synaptic Neurosci ISSN: 1663-3563
Effect of adrenergic receptor activation on IPSC frequency.
| Recording condition | Control frequency (Hz) | NE/agonist frequency (Hz) | df | % of control | df | ||||
|---|---|---|---|---|---|---|---|---|---|
| sIPSCs NE (KCl int.) | 14.65 ± 2.49 | 22.32 ± 2.65 | 4.77 | 12 | 0.0005∗ | 177.19 ± 22.21 | 3.48 | 12 | 0.005∗ |
| sIPSCs NE | 42.39 ± 3.89 | 54.32 ± 3.59 | 5.15 | 12 | 0.0002∗ | 134.83 ± 8.31 | 4.19 | 12 | 0.001∗ |
| mIPSCs NE | 15.09 ± 1.56 | 20.73 ± 2.35 | 4.85 | 18 | 0.0001∗ | 139.65 ± 6.19 | 6.41 | 18 | <0.0001∗ |
| sIPSCs PHE | 29.93 ± 4.33 | 36.39 ± 5.70 | 1.89 | 9 | 0.09 | 121.57 ± 13.84 | 1.56 | 9 | 0.15 |
| mIPSCs PHE | 8.19 ± 2.29 | 8.11 ± 1.65 | 0.1 | 5 | 0.93 | 111.02 ± 8.98 | 1.23 | 5 | 0.27 |
| sIPSCs UK14304 | 35.25 ± 7.46 | 32.12 ± 6.20 | 1.78 | 6 | 0.13 | 93.54 ± 3.95 | 1.63 | 6 | 0.15 |
| mIPSCs UK14304 | 14.12 ± 1.45 | 14.58 ± 1.27 | 0.34 | 5 | 0.75 | 106.05 ± 7.05 | 0.69 | 5 | 0.52 |
| sIPSCs Isoprenaline | 19.12 ± 4.14 | 18.62 ± 3.49 | 0.45 | 4 | 0.67 | 101.75 ± 3.83 | 0.36 | 4 | 0.74 |
| mIPSCs Isoprenaline | 12.97 ± 3.63 | 13.19 ± 2.98 | 0.19 | 6 | 0.86 | 105.94 ± 6.78 | 0.88 | 6 | 0.40 |
Effect of adrenergic receptor activation on IPSC amplitude.
| Recording condition | Control amplitude (pA) | NE/agonist amplitude (pA) | df | % of control | df | ||||
|---|---|---|---|---|---|---|---|---|---|
| sIPSCs NE (KCl int.) | 48.04 ± 5.54 | 71.90 ± 8.12 | 3.2 | 12 | 0.008∗ | 167.04 ± 30.27 | 2.22 | 12 | 0.047∗ |
| sIPSCs NE | 57.90 ± 9.34 | 80.61 ± 11.57 | 4.61 | 12 | 0.0006∗ | 148.99 ± 12.66 | 3.87 | 12 | 0.002∗ |
| mIPSCs NE | 41.35 ± 1.82 | 42.20 ± 2.06 | 1.24 | 18 | 0.23 | 101.94 ± 1.77 | 1.1 | 18 | 0.29 |
| sIPSCs PHE | 57.09 ± 4.02 | 60.66 ± 9.19 | 0.48 | 9 | 0.64 | 105.49 ± 11.68 | 0.47 | 9 | 0.65 |
| mIPSCs PHE | 31.90 ± 2.52 | 30.28 ± 3.75 | 1.1 | 5 | 0.32 | 93.32 ± 5.65 | 1.18 | 5 | 0.29 |
| sIPSCs UK14304 | 59.81 ± 8.84 | 53.55 ± 3.98 | 0.78 | 6 | 0.47 | 97.62 ± 9.87 | 0.24 | 6 | 0.82 |
| mIPSCs UK14304 | 39.81 ± 1.75 | 38.91 ± 2.27 | 0.7 | 5 | 0.52 | 97.59 ± 2.56 | 0.81 | 5 | 0.45 |
| sIPSCs Isoprenaline | 59.74 ± 6.50 | 59.52 ± 10.39 | 0.03 | 4 | 0.98 | 97.77 ± 9.00 | 0.2 | 4 | 0.85 |
| mIPSCs Isoprenaline | 35.78 ± 1.18 | 35.92 ± 1.25 | 0.12 | 6 | 0.91 | 100.63 ± 3.17 | 0.20 | 6 | 0.85 |
Effect of adrenergic receptor activation on IPSC decay time.
| Recording condition | Control decay time (ms) | NE/agonist decay time (ms) | df | % of control | df | ||||
|---|---|---|---|---|---|---|---|---|---|
| sIPSCs NE (KCl int.) | 7.13 ± 0.48 | 7.46 ± 0.54 | 2.11 | 12 | 0.06 | 104.47 ± 2.27 | 1.97 | 12 | 0.07 |
| sIPSCs NE | 8.91 ± 0.50 | 9.18 ± 0.52 | 0.73 | 12 | 0.48 | 103.93 ± 3.92 | 1 | 12 | 0.34 |
| mIPSCs NE | 7.08 ± 0.25 | 7.80 ± 0.29 | 6.03 | 18 | <0.0001∗ | 110.44 ± 1.57 | 6.67 | 18 | <0.0001∗ |
| sIPSCs PHE | 8.62 ± 0.50 | 9.16 ± 0.49 | 1.79 | 9 | 0.11 | 107.04 ± 3.50 | 2.01 | 9 | 0.08 |
| mIPSCs PHE | 8.08 ± 1.07 | 8.64 ± 0.97 | 1.9 | 5 | 0.16 | 108.55 ± 4.40 | 1.95 | 5 | 0.11 |
| sIPSCs UK14304 | 8.28 ± 0.43 | 8.06 ± 0.28 | 0.96 | 6 | 0.37 | 98.03 ± 2.81 | 0.7 | 6 | 0.51 |
| mIPSCs UK14304 | 6.76 ± 0.46 | 7.32 ± 0.46 | 4.92 | 5 | 0.004∗ | 108.52 ± 1.63 | 4.53 | 5 | 0.006∗ |
| sIPSCs Isoprenaline | 7.46 ± 0.65 | 7.92 ± 0.66 | 1.33 | 4 | 0.25 | 106.57 ± 3.72 | 1.4 | 4 | 0.24 |
| mIPSCs Isoprenaline | 7.79 ± 0.35 | 8.12 ± 0.27 | 2.01 | 6 | 0.09 | 104.68 ± 2.35 | 1.99 | 6 | 0.07 |
Effect of glucocorticoids on frequency of inhibitory synaptic transmission.
| Recording type | Control (Hz ± SEM) | Dex -1 μM (Hz ± SEM) | df ( | % of control | df | ||||
|---|---|---|---|---|---|---|---|---|---|
| sIPSCs Dex – 1 μM | 16.38 ± 2.26 | 14.4 ± 2.28 | 2.42 | 8 | 0.04∗ | 87.01 ± 4.94 | 2.63 | 8 | 0.03∗ |
| sIPSCs Dex – 10 nM | 21.74 ± 4.92 | 19.21 ± 4.18 | 0.84 | 5 | 0.44 | 94.82 ± 9.79 | 0.53 | 5 | 0.62 |
| sIPSCs Dex – 100 nM | 30.87 ± 4.74 | 31.60 ± 5.71 | 0.28 | 8 | 0.79 | 99.88 ± 7.39 | 0.02 | 8 | 0.99 |
| mIPSCs | 11.49 ± 2.21 | 11.01 ± 2.67 | 0.58 | 5 | 0.59 | 91.51 ± 7.50 | 1.13 | 5 | 0.31 |
| sIPSCs Cort -1 μM | 26.55 ± 3.46 | 22.44 ± 3.90 | 3.5 | 7 | 0.01∗ | 81.05 ± 5.6 | 3.39 | 7 | 0.01∗ |
Effect of glucocorticoids on amplitude of inhibitory synaptic transmission.
| Recording type | Control (pA ± SEM) | Dex – 1 μM (pA ± SEM) | df ( | % of control | df | ||||
|---|---|---|---|---|---|---|---|---|---|
| sIPSCs Dex – 1 μM | 51.37 ± 3.87 | 48.45 ± 4.04 | 1.08 | 8 | 0.31 | 95.11 ± 5.41 | 0.91 | 8 | 0.39 |
| sIPSCs Dex – 10 nM | 58.34 ± 9.44 | 60.66 ± 12.27 | 0.42 | 5 | 0.69 | 103.56 ± 7.85 | 0.45 | 5 | 0.67 |
| sIPSCs Dex – 100 nM | 70.83 ± 9.19 | 62.45 ± 8.28 | 1.33 | 8 | 0.22 | 90.38 ± 7.17 | 1.34 | 8 | 0.22 |
| mIPSCs | 37.31 ± 3.93 | 36.28 ± 3.69 | 0.49 | 5 | 0.65 | 98.24 ± 4.53 | 0.39 | 5 | 0.71 |
| sIPSCs Cort – 1 μM | 54.85 ± 5.7 | 47.65 ± 4.72 | 1.96 | 7 | 0.09 | 89.21 ± 5.86 | 1.84 | 7 | 0.11 |
Effect of glucocorticoids on decay time of inhibitory synaptic transmission.
| Recording type | Control (ms ± SEM) | Dex – 1 μM (ms ± SEM) | df ( | % of control | df | ||||
|---|---|---|---|---|---|---|---|---|---|
| sIPSCs Dex – 1 μM | 7.99 ± 1.0 | 7.70 ± 0.72 | 0.73 | 8 | 0.49 | 101.39 ± 6.91 | 0.2 | 8 | 0.85 |
| sIPSCs Dex – 10 nM | 7.46 ± 0.62 | 7.62 ± 0.56 | 0.86 | 5 | 0.43 | 103.02 ± 2.83 | 1.07 | 5 | 0.34 |
| sIPSCs Dex – 100 nM | 7.46 ± 0.60 | 7.95 ± 0.67 | 1.82 | 8 | 0.11 | 106.84 ± 3.33 | 2.05 | 8 | 0.07 |
| mIPSCs | 6.59 ± 0.50 | 6.92 ± 0.56 | 1.46 | 5 | 0.2 | 104.94 ± 3.30 | 1.5 | 5 | 0.19 |
| sIPSCs Cort – 1 μM | 10.59 ± 0.70 | 9.79 ± 0.61 | 1.53 | 7 | 0.17 | 93.40 ± 4.58 | 1.44 | 7 | 0.19 |
Effect of adrenergic receptor activation on IPSC frequency with and without Dex pre-treatment.
| Control (Hz) | NE/PHE (Hz) | NE/PHE+Dex (Hz) | Con vs. NE/PHE | Con vs. NE/PHE+Dex | NE/PHE vs. NE/PHE+Dex | ||||
|---|---|---|---|---|---|---|---|---|---|
| NE+Dex | 42.39 ± 3.89 | 54.32 ± 3.59 | 52.31 ± 4.16 | 11.77 | 11 | 0.002∗ | ∗∗ | ∗ | NS |
| PHE+Dex | 29.93 ± 4.33 | 36.39 ± 5.70 | n/a | df = 9 | 0.09 | NS | n/a | n/a | |
| Dex+NE | 37.83 ± 4.49 | 34.24 ± 3.94 | 51.25 ± 5.87 | 42.61 | 15 | <0.0001∗ | ∗ | ∗∗∗∗ | ∗∗∗∗ |
| Dex+PHE | 25.62 ± 2.82 | 23.69 ± 2.63 | 37.79 ± 3.37 | 51.73 | 15 | <0.0001∗ | ∗∗ | ∗∗∗∗ | ∗∗∗∗ |
Effect of adrenergic receptor activation on IPSC amplitude with and without Dex pre-treatment.
| Control (pA) | NE/Agonist (pA) | NE/Agonist+Dex (pA) | Con vs. NE/PHE | Con vs. NE/PHE+Dex | NE/PHE vs. NE/PHE+Dex | ||||
|---|---|---|---|---|---|---|---|---|---|
| NE+Dex | 57.90 ± 9.34 | 80.61 ± 11.57 | 68.58 ± 13.56 | 7.11 | 11 | 0.007∗ | ∗∗ | NS | NS |
| PHE+Dex | 57.09 ± 4.02 | 60.66 ± 9.19 | n/a | df = 9 | 0.64 | NS | n/a | n/a | |
| Dex+NE | 49.38 ± 2.52 | 49.60 ± 4.04 | 73.63 ± 8.72 | 13.44 | 15 | 0.001∗ | NS | ∗∗ | ∗∗ |
| Dex+ PHE | 52.75 ± 3.74 | 51.55 ± 4.19 | 59.62 ± 5.10 | 6.14 | 15 | 0.01∗ | NS | ∗ | ∗ |
Chi-square comparison of NE-alone vs. Dex-primed NE.
| Chi-square | Increased frequency | No change in frequency | df | Significance | ||
|---|---|---|---|---|---|---|
| NE-Alone | 10 | 3 | 3.88 | 1 | 0.05–0.02 | ∗ |
| Dex-Primed | 15 | 0 |
Chi-square comparison of PHE-alone vs. Dex-primed PHE.
| Chi-square | Increased frequency | No change in frequency | df | Significance | ||
|---|---|---|---|---|---|---|
| PHE-Alone | 5 | 5 | 9.38 | 1 | 0.01–0.001 | ∗∗ |
| Dex-Primed | 15 | 0 |